Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Sanara MedTech Inc. made materially false and/or misleading statements and/or failed to disclose that: On November 11, 2025, Sanara announced that it would be “discontinuing operations of [its Tissue Health Plus (“THP”) program] to improve its operating efficiency and reallocate resources to its core surgical business.” The following day, before market hours, Sanara released its third quarter 2025 financial results, reporting that its “net loss from discontinued operations . . . was $31.2 million,” which “includes a noncash asset impairment charge of $26.5 million . . . related to the discontinued operations of THP.” Following this news, Sanara’s stock price fell over 24% on November 12, 2025.
In order to be eligible to join the SMTI class action lawsuit, you must have incurred a loss on shares of Sanara MedTech Inc. purchased during the class period listed above.
TOP
